THE LEADING RESEARCH REPORTS DISTRIBUTION
NETWORK

icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research

Metastatic Triple Negative Breast Cancer (mTNBC) Market 2030: Epidemiology Analysis, Key Companies, Emerging Drugs and Competitive Analysis by DelveInsight

Apr 28, 2021 9:00 AM ET

Metastatic Triple Negative Breast Cancer (mTNBC) Market 2030: Epidemiology Analysis, Key Companies, Emerging Drugs and Competitive Analysis by DelveInsight

DelveInsight’s “Metastatic Triple Negative Breast Cancer (mTNBC)” report delivers an in-depth understanding of the Metastatic Triple Negative Breast Cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer  market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Get Sample Copy of Metastatic Triple Negative Breast Cancer Market

Key Highlights from the Metastatic Triple Negative Breast Cancer Market Report

  • Total Diagnosed Incident cases of Triple Negative Breast Cancer in the 7MM countries was 99,380 in 2017.
  • Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC followed by France and Italy in the year 2017.
  • Out of the total cases of Triple Negative Breast Cancer, more than 8000 cases were in the advanced stage in the US in 2017.
  • Key Pipeline therapies in the Metastatic Triple Negative Breast Cancer market are Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), and others anticipated to enter the market in the next decade.
  • Key companies proactively working in the mTNBC market include Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, among others.

Metastatic Triple Negative Breast Cancer (mTNBC) market report provides current treatment practices, emerging drugs, Metastatic Triple Negative Breast Cancer (mTNBC) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy market Size from 2018 to 2030 segmented by seven major markets. 

The Report also lays forward current mTNBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Metastatic Triple Negative Breast Cancer: Disease Overview

Metastatic Triple Negative Breast Cancer is characterized as a metastatic tumor in which the estrogen and progesterone (ER/PR) receptors are negative by immunohistochemistry (IHC) and

there is no overexpression of HER2 by immunohistochemistry (IHC) or no gene amplification by fluorescence in situ hybridization technique. TNBC (ER-PR-HER2-) and other breast cancers have different epidemiological risk factor profiles.

According to breastcancer.org, about 70% of breast cancers diagnosed in people who have an inherited BRCA mutation, particularly BRCA1, are triple-negative.

TNBCs are slightly larger and of higher grade than non-TNBCs, according to secondary sources, but they are less likely to have lymph node metastases.

Metastatic Triple Negative Breast Cancer Epidemiology Segmentation

DelveInsight’s Metastatic Triple Negative Breast Cancer Market Report proffers historical as well as forecasted insights into the epidemiology of the indication for the study period 2018-30 in the 7MM segmented into:

  • Metastatic Triple Negative Breast Cancer Total Incidence Cases
  • Metastatic Triple Negative Breast Cancer Subtype Specific Cases
  • Metastatic Triple Negative Breast Cancer Stage Specific Cases
  • Metastatic Triple Negative Breast Cancer Diagnosed and Treatable Cases
  • Metastatic Triple Negative Breast Cancer Gene Mutation Specific Cases 

Request for Sample Pages: Metastatic Triple Negative Breast Cancer Market Insight

Metastatic Triple Negative Breast Cancer Treatment Landscape 

Currently, the treatment paradigm for mTNBC includes few treatment options such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery and radiation.

Few US FDA approved drugs, such as:

  • Keytruda (Pembrolizumab): Merck Sharpe and Dohme
  • Lynparza (Olaparib): AstraZeneca
  • Tecentriq (Atezolizumab): Hoffmann-La Roche
  • Talzenna (talazoparib): Pfizer
  • Trodelvy: Gilead Sciences.

Various off label drugs are used for treating mTNBC which include: 

  • Paclitaxel (Abraxane)
  • Erbulin (Halaven)
  • Carboplatin
  • Cisplatin
  • Docetaxel 

Metastatic Triple Negative Breast Cancer Market

  • Market Size of mTNBC in the 7MM was USD 438 Million in 2017.
  • Among the EU-5 countries, Germany accounted for the highest market size for mTNBC in 2017
  • The United States accounted for the largest mTNBC market size, in comparison to the other 7MM countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), Japan.
  • The mTNBC market size of the first line of therapy (LoT) was estimated to be higher than that of the second line of therapy.

Metastatic Triple Negative Breast Cancer Market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, and several others. The launch of Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), etc. is anticipated to provide a major push to the growth of the mTNBC market size in the forecast period 2018-30 in the 7MM. 

Learn more about market insights @ mTNBC Market Analysis, and Forecast  

Metastatic Triple Negative Breast Cancer Emerging Drugs

  • Ipatasertib (RG7440): Hoffmann-La Roche 
  • IPI-549 (Eganelisib): Infinity Pharmaceuticals
  • Pembrolizumab (Imprime PGG): HiberCell
  • Leronlimab (PRO 140): CytoDyn
  • CFI-400945: Treadwell Therapeutics

Metastatic Triple Negative Breast Cancer Market Drivers

  • Advancements in Genomics and Proteomics
  • Emergence of Immunotherapies
  • Improved Treatment Deliverance
  • Increase in Number of Research Articles

Metastatic Triple Negative Breast Cancer Market Barriers

  • Use of Off Label Therapies and Generics
  • High Treatment Cost
  • Fewer Patients Available for Clinical Trials
  • High Recurrence Rate
  • Multiple Treatment Challenges 

To learn more, visit Metastatic Triple Negative Breast Cancer Market Insights and Forecasted Trends  

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Key Companies in mTNBC Market: Hoffmann-La Roche, Infinity Pharmaceuticals, HiberCell, CytoDyn, Treadwell Therapeutics, and several others. 

Key mTNBC Pipeline therapies: Ipatasertib (RG7440), IPI-549 (Eganelisib), Pembrolizumab (Imprime PGG), Leronlimab (PRO 140), CFI-400945 and several others.

mTNBC Market Segmentation: By Geography, By mTNBC therapies

Analysis: Comparative and conjoint analysis of mTNBC emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting 

Table of Contents

1.Key Insights
2.Triple Negative Breast Cancer Market Overview at a Glance
3.Disease Background and Overview: Triple Negative Breast Cancer
4.Unmet Needs
5.Epidemiology and Patient Population
6.Country Wise-Epidemiology of TNBC
7.Treatment Practices
8.Marketed Drug Analysis
9.Emerging Therapies
10.Metastatic Triple Negative Breast Cancer (mTNBC): 7MM Market Analysis
11.Market Outlook by Country
12.Market Drivers
13.Market Barriers
14.Appendix
15.DelveInsight Capabilities
16.Disclaimer
17.About DelveInsight

Related Reports 

Metastatic Bone Pain Market

DelveInsight’s “Metastatic Bone Pain – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Castration Resistant Prostate Cancer Market

DelveInsight’s “Metastatic Castration Resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Castration-Sensitive Prostate Cancer Market

DelveInsight’s “Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Colorectal Cancer Market

Get comprehensive historical and forecast analysis of Metastatic Colorectal Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Merck, Eli Lilly, Bristol-Myers Squibb, Amgen, Taiho Oncology, Pfizer, Isofol Medical, Ab Science, Effector Therapeutics, Vaximm, Cardiff Oncology, others.

Metastatic Cutaneous Squamous Cell Cancer Market

DelveInsight’s “Metastatic Cutaneous Squamous Cell Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Hepatocellular Carcinoma Market

DelveInsight’s “Metastatic Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic HER2 Positive Breast Cancer Market

DelveInsight’s “Metastatic HER2 Positive Breast Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Melanoma Market

DelveInsight’s “Metastatic Melanoma – Market Insights, Epidemiology, and Market Forecast-2030” report.

Metastatic Merkel Cell Carcinoma Market

DelveInsight’s “Metastatic Merkel Cell Carcinoma- Market Insights, Epidemiology, and Market Forecast-2030″ report.

Metastatic Prostate Cancer Market

DelveInsight’s “Metastatic Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030” report.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Visit for more insights into Pharma, Healthcare and Biotech News

Connect With Us at:

LinkedIn | Facebook | Twitter